An increase in OGF-OGFr activity in cancer cells by i) addition of exogenous OGF [14-19], ii) treatment with imidazoquinoline compounds such as imiquimod and resiquimod [24], or iii) transfection of sense cDNA for OGFr [26-29], depresses cell proliferation. The gene discussed is PENK; the disease is cancer.